Related Experiment Video
Updated: Nov 9, 2025
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and
Rodolfo Pedro Rothlin1, Mariano Duarte2, Facundo Germán Pelorosso3
1Sociedad Argentina de Farmacología Clínica, Asociación Médica Argentina, Buenos Aires, Argentina.
Abstract:
COVID-19 pandemic demands a swift response to find therapeutic tools that effectively reduce morbidity and mortality. Despite initial fears, evidence from retrospective observational studies supports the inhibition of the renin-angiotensin system as an emerging pathway to delay or moderate angiotensin II-driven lung inflammation. This has triggered several prospective clinical trials. In this commentary we provide an overview and analysis of current ongoing clinical trials aimed at evaluating the therapeutic efficacy of angiotensin receptor blocker (ARB) use in COVID-19. The relevance of the results of these trials will have to be interpreted depending on the stage and severity of the disease and in light of the start time of their prescription related to the time of diagnosis of COVID-19 as well as the administered doses.
Insights
Angiotensin receptor blockers (ARBs) may moderate COVID-19 lung inflammation by inhibiting the renin-angiotensin system. Clinical trials are evaluating ARB efficacy based on disease severity and treatment timing.
Area of Science:
- Cardiovascular Medicine
- Infectious Diseases
- Pharmacology
Background:
- The COVID-19 pandemic necessitates rapid identification of effective therapeutic interventions.
- Retrospective studies suggest inhibiting the renin-angiotensin system may mitigate angiotensin II-induced lung inflammation in COVID-19 patients.
- This has prompted the initiation of clinical trials to investigate this therapeutic pathway.
Purpose of the Study:
- To provide an overview and analysis of ongoing clinical trials.
- To evaluate the therapeutic efficacy of angiotensin receptor blockers (ARBs) in the context of COVID-19.
- To discuss the interpretation of trial results concerning disease stage, severity, and treatment parameters.
Main Methods:
- Review and analysis of current prospective clinical trials.
- Examination of studies investigating angiotensin receptor blocker (ARB) use in COVID-19 patients.
- Assessment of factors influencing therapeutic outcomes, including disease stage, severity, and treatment initiation timing.
Main Results:
- Evidence suggests a potential role for ARBs in managing COVID-19-related lung inflammation.
- Ongoing clinical trials are actively investigating the efficacy of ARBs.
- Interpretation of results requires careful consideration of disease-specific variables.
Conclusions:
- Angiotensin receptor blockers (ARBs) represent a potential therapeutic strategy for COVID-19.
- The clinical utility of ARBs in COVID-19 requires further validation through ongoing trials.
- Contextualizing trial outcomes based on disease characteristics is crucial for understanding ARB effectiveness.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...